Chronic Hepatitis B Market Size and Growth Forecast for Businesses 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Chronic Hepatitis B Market Covering 2025–2034?

The chronic hepatitis B market has experienced consistent growth over recent years. Projections indicate an expansion from $3.77 billion in 2024 to $3.93 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 4.2%. This historical expansion is primarily due to breakthroughs in antiviral treatments, increasing government and non-governmental organization (NGO) programs, enhanced diagnostic methods, the rising incidence of HIV, and heightened public knowledge.

The chronic hepatitis b market size is projected to experience consistent growth over the coming years. It is expected to expand to “$4.59 billion by 2029, achieving a compound annual growth rate (CAGR) of 4.0%. This anticipated growth throughout the forecast period stems from factors such as the expansion into emerging markets, increasing governmental policies and financial support, advancements in diagnostics and screening, rising healthcare expenditure, a surge in strategic collaborations and partnerships, an expanding aging population, and an increase in public awareness initiatives. Prominent trends for the forecast period include a shift towards curative treatment options, further expansion within emerging markets, enhanced diagnostic and screening capabilities, stronger partnerships and collaborations, and a dedicated focus on patient-centric care.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp

What Are The Top Growth Drivers Impacting The Chronic Hepatitis B Market Outlook?

The increasing prevalence of chronic hepatitis B infection is anticipated to stimulate the growth of the chronic hepatitis B virus market moving forward. Hepatitis B is a liver condition caused by the hepatitis B virus (HBV), which can be prevented through vaccination. The rise in hepatitis B infection rates is attributed to a combination of elements, especially in low- and middle-income regions, due to inadequate vaccination coverage resulting in higher transmission rates as many people remain unprotected. An uptick in hepatitis B infection rates is likely to enhance the demand for diagnostic tests and treatment options. For instance, in June 2024, a report from the Centers for Disease Control and Prevention (CDC), a US-based government agency, stated that raising global hepatitis B vaccination coverage to 90% and treatment access to 80% could prevent 26 million new infections and 9 million deaths associated with hepatitis B between 2022 and 2050. In 2022, there were 1.2 million new cases of hepatitis B virus (HBV) infection. Therefore, the significant occurrence of hepatitis B infection will boost the chronic hepatitis B virus market.

What Are The Primary Types Of Segments Analyzed In The Chronic Hepatitis B Market?

The chronic hepatitis bmarket covered in this report is segmented –

1) By Drug Class: Antivirals; Immune Modulators

2) By Gender: Male; Female

3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers

Subsegments:

1) By Antivirals: Nucleos(T)Ide Analogs (Tenofovir, Entecavir); Interferons (Pegylated Interferon)

2) By Immune Modulators: Immune Checkpoint Inhibitors; Therapeutic Vaccines (HBV Vaccines Under Development)

What Are The Major Trends Driving The Growth Of The Chronic Hepatitis B Market?

Leading companies active in the chronic hepatitis B market are prioritizing technological progress, including the development of novel antiviral therapies. These innovative antiviral treatments are advanced medications designed to combat viral infections, particularly those that are drug-resistant, through mechanisms like inhibiting viral replication and utilizing sophisticated delivery methods. Their safety and effectiveness are currently being evaluated in clinical trials, with bepirovirsen being an example for chronic hepatitis B. A notable illustration occurred in February 2024, when GSK plc, a UK-based global pharmaceutical and biotechnology firm involved in the research, development, production, and promotion of various healthcare products, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for bepirovirsen. This investigational antisense oligonucleotide (ASO) is under investigation for treating chronic hepatitis B (CHB). Bepirovirsen operates by targeting and breaking down the RNA of the hepatitis B virus (HBV), which could enable the body’s immune system to re-establish control over the infection. The medication has shown encouraging outcomes in its Phase IIb trials, specifically in the B-Clear and B-Sure studies, exhibiting effectiveness in lowering hepatitis B surface antigen (HBsAg) levels and attaining sustained suppression of the virus.

Who Are The Top Performing Companies In The Chronic Hepatitis B Market In Recent Years?

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Chronic Hepatitis B Market?

North America was the largest region in the chronic hepatitis B market in 2024. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Chronic Hepatitis B Market Report:

https://www.thebusinessresearchcompany.com/customise?id=17112&type=smp

Browse Through More Reports Similar to the Global Chronic Hepatitis B Market 2025, By The Business Research Company

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Chronic Lower Back Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795